Leonid Bukhman, MD
Family Medicine · New York, NYNPI 1144334699
Payments from drug & device makers
Across 307 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$768
- Lilly USA, LLC$765
- Novo Nordisk$679
- AstraZeneca$642
- GSK$336
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,136100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $2,079 |
| Amgen(2 entities) | 37 | $768 |
| Lilly USA, LLC | 35 | $765 |
| Novo Nordisk | 22 | $679 |
| AstraZeneca | 33 | $642 |
| GSK | 18 | $336 |
| Amarin Pharma, Inc. | 14 | $278 |
| Pfizer | 12 | $264 |
| Bayer | 6 | $216 |
| Scilex Pharmaceuticals Inc. | 7 | $156 |
| Sanofi | 4 | $148 |
| Boehringer Ingelheim | 5 | $106 |
| Gilead | 5 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $94 |
| Phathom Pharmaceuticals, Inc. | 5 | $79 |
| Nestle Healthcare Nutrition Inc. | 3 | $69 |
| Astellas Pharma US Inc | 3 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 1 | $28 |
| Ironwood Pharmaceuticals, Inc | 1 | $27 |
| Endo Pharmaceuticals Inc. | 1 | $25 |
| Nevro Corp. | 1 | $22 |
| Merck | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Smith+Nephew | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,136 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 81 | $358,248 |
| Diclofenac Sodium | 514 | $258,516 |
| JanuviaSitagliptin Phosphate | 143 | $153,157 |
| Metformin Er GastricMetformin Hcl | 80 | $148,814 |
| EliquisApixaban | 106 | $125,593 |
| LinzessLinaclotide | 105 | $116,080 |
| MounjaroTirzepatide | 52 | $100,862 |
| OzempicSemaglutide | 66 | $100,649 |
| TrulicityDulaglutide | 49 | $96,137 |
| VascepaIcosapent Ethyl | 119 | $75,343 |
| JardianceEmpagliflozin | 77 | $72,904 |
| TradjentaLinagliptin | 62 | $65,395 |
| DexilantDexlansoprazole | 70 | $59,643 |
| UbrelvyUbrogepant | 27 | $50,374 |
| MyrbetriqMirabegron | 61 | $44,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Ubrelvy, Restasis | $2,079 | $549,688232 claims |
| MerckJanuvia, Janumet, Janumet Xr | $21 | $215,920194 claims |
| Lilly USA, LLCMounjaro, Trulicity | $765 | $196,998101 claims |
| PfizerEliquis, Nurtec Odt | $264 | $155,326120 claims |
| Boehringer IngelheimJardiance, Tradjenta | $106 | $138,299139 claims |
| Novo NordiskOzempic, Rybelsus | $679 | $133,69889 claims |
| AstraZenecaSymbicort, Farxiga, Brilinta, Breztri Aerosphere | $642 | $104,471149 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $336 | $62,46660 claims |
| Astellas Pharma US IncMyrbetriq | $61 | $44,70461 claims |
| Redhill Biopharma Inc.Movantik | $19 | $22,33028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in New York
- Matthew PabisNew York$222K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
- Jason KindtNew York$122K
- Punyadech PhotangthamNew York$107K
- Mahyar EidgahNew York$76K
- Anthony LyonNew York$65K
- Daniel BowersNew York$44K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.